Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Shares Gap Down After Analyst Downgrade

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)’s stock price gapped down before the market opened on Tuesday after Jefferies Financial Group downgraded the stock from a moderate sell rating to a strong sell rating. The stock had previously closed at $24.59, but opened at $22.57. Fresenius Medical Care AG & Co. KGaA shares last traded at $23.0760, with a volume of 508,488 shares traded.

Several other equities analysts have also recently commented on the company. Erste Group Bank cut Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. Weiss Ratings downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 5th. Truist Financial set a $28.00 price objective on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Monday, January 5th. Zacks Research cut shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Finally, The Goldman Sachs Group cut shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 20th. Five investment analysts have rated the stock with a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce” and an average target price of $28.00.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Hedge funds and other institutional investors have recently made changes to their positions in the business. Pzena Investment Management LLC lifted its position in Fresenius Medical Care AG & Co. KGaA by 1.0% during the 3rd quarter. Pzena Investment Management LLC now owns 14,816,852 shares of the company’s stock worth $390,128,000 after buying an additional 153,870 shares in the last quarter. Morgan Stanley increased its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 47.2% in the fourth quarter. Morgan Stanley now owns 2,939,839 shares of the company’s stock valued at $70,027,000 after purchasing an additional 942,497 shares in the last quarter. Todd Asset Management LLC raised its position in Fresenius Medical Care AG & Co. KGaA by 5.2% in the 3rd quarter. Todd Asset Management LLC now owns 1,303,424 shares of the company’s stock worth $34,319,000 after purchasing an additional 64,311 shares during the last quarter. Teachers Retirement System of The State of Kentucky raised its position in Fresenius Medical Care AG & Co. KGaA by 8.3% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 816,200 shares of the company’s stock worth $21,491,000 after purchasing an additional 62,700 shares during the last quarter. Finally, Integral Health Asset Management LLC lifted its holdings in Fresenius Medical Care AG & Co. KGaA by 44.4% during the 4th quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock worth $15,483,000 after buying an additional 200,000 shares in the last quarter. 8.37% of the stock is currently owned by institutional investors and hedge funds.

Fresenius Medical Care AG & Co. KGaA Price Performance

The stock has a market capitalization of $13.57 billion, a P/E ratio of 12.26, a price-to-earnings-growth ratio of 0.72 and a beta of 0.90. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.00 and a current ratio of 1.36. The stock has a 50-day simple moving average of $23.30 and a 200 day simple moving average of $24.46.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its earnings results on Tuesday, February 24th. The company reported $0.83 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.16. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.71% and a net margin of 5.03%.The company had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $4.80 billion. On average, equities analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current fiscal year.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.